Feasibility of a Community-Based Multimodal Exercise Programme in Parkinson's Disease
Feasibility and Preliminary Effectiveness of an Individualised Multimodal Group-Based Exercise Programme for People With Parkinson's Disease: A Non-Randomized Feasibility Study
This study aims to evaluate the feasibility and preliminary effectiveness of a multimodal, group-based but individualised therapeutic exercise programme for people with Parkinson's disease delivered within a real-world community-based patient association setting.
The primary objective is to assess the feasibility of implementing the programme, including recruitment, consent, adherence, intervention completion, acceptability, perceived exertion and safety. Secondary objectives are to obtain preliminary comparative information regarding the effects of the intervention on motor and non-motor symptoms, physical fitness, pain-related outcomes and exercise-induced hypoalgesia.
This is a non-randomized sequential feasibility study including an intervention group participating in a 12-week multimodal exercise programme and a matched non-exercise control group maintaining usual activities. Outcomes will be assessed at baseline, post-intervention and 6-month follow-up.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder characterised by motor symptoms such as bradykinesia, rigidity and tremor, as well as non-motor symptoms including pain, fatigue, sleep disturbances, cognitive impairment and psychiatric symptoms. Although pharmacological management is effective for several motor manifestations, many non-motor symptoms respond poorly to dopaminergic therapy, highlighting the need for complementary non-pharmacological interventions.
Exercise therapy has shown beneficial effects on both motor and non-motor symptoms in people with Parkinson's disease. However, it remains necessary to determine whether exercise programmes supported by the scientific literature can be feasibly implemented within real-world community environments frequently attended by patients, such as Parkinson's disease associations. In these settings, exercise interventions are commonly delivered in generic group-based formats despite the substantial heterogeneity in symptom severity, functional capacity and disease progression among participants. Therefore, there is also a need to design exercise programmes that allow individualised adjustment of exercise prescription parameters, including intensity and progression criteria, in order to optimize the potential effects of exercise on Parkinson's disease symptoms while maintaining safety and feasibility in community-based group settings.
The present study aims to evaluate the feasibility of implementing a multimodal, group-based but individualised therapeutic exercise programme within a real-world Parkinson's disease association setting. Feasibility outcomes include consent and recruitment rates, adherence, intervention completion, trial completion, acceptability, perceived exertion, treatment-decision rate and safety. Control group recruitment and assessment completion will be reported descriptively as operational information related to the exploratory comparison group, but they will not determine the primary feasibility assessment of the intervention.
Secondary objectives are to obtain preliminary comparative information regarding the potential effectiveness of the intervention on motor and non-motor symptoms, gait, balance, physical fitness, pain-related outcomes and exercise-induced hypoalgesia.
This study uses a non-randomized sequential feasibility design. Recruitment of the intervention group as a cohort was necessary to implement the group exercise programme under realistic conditions and to evaluate intervention-related feasibility outcomes. To provide preliminary comparative information regarding effectiveness, a matched non-exercise control group was included.
Frequency matching will be used at the group level according to sex, 10-year age categories and Hoehn & Yahr stage categories (1-1.5, 2-2.5 and 3). Individual 1:1 matching will not be required. This approach was selected to reduce baseline imbalance while maintaining the feasibility of recruitment within a real-world community setting.
The sample size was determined according to the primary feasibility objective, specifically the precision of the estimated adherence rate. Assuming an expected adherence rate of approximately 80%, 28 participants would provide an estimation precision of approximately ±15% with a 95% confidence interval. Considering potential attrition, the intervention group sample size was increased to 32 participants. A matched non-exercise control group of 32 participants will also be recruited, resulting in a total target sample size of 64 participants.
Participants with Hoehn & Yahr stages 1-3 will be recruited from Asociación Parkinson Madrid and other Parkinson's disease associations in the Madrid region.
The intervention group will participate in a 12-week multimodal exercise programme consisting of two weekly supervised face-to-face sessions and one weekly home-based session. The programme includes strength training, cardiovascular/balance exercise and cognitive-motor exercises. Exercise prescription and progression were individualised according to participant tolerance, functional capacity, motor performance, and safety considerations.
Training intensity was monitored and adjusted using 10-repetition maximum principles, repetitions in reserve (RIR), and perceived exertion scales including OMNI-RES and Borg ratings. Exercise prescription and progression were individualised according to participant tolerance, functional capacity, motor performance, and safety considerations. All supervised sessions were delivered by physiotherapists experienced in neurological rehabilitation and exercise prescription for Parkinson's disease.
Outcomes will be assessed at baseline, post-intervention and 6-month follow-up.
Feasibility outcomes will be analysed descriptively using frequencies, percentages, means and confidence intervals where appropriate. Secondary clinical outcomes measured at baseline, post-intervention and 6-month follow-up will be analysed using linear mixed-effects models including group, time and group-by-time interaction effects. Estimated between-group differences, 95% confidence intervals and effect sizes will be reported. Given the feasibility nature of the study and the non-randomized sequential design, efficacy analyses will be interpreted as exploratory and hypothesis-generating rather than confirmatory.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Mario González Iglesias, MSc PhD Student, Physiotherapy
- Telefonnummer: +34 622113365
- E-Mail: mario.gonzalez@urjc.es
Studieren Sie die Kontaktsicherung
- Name: Yeray González Zamorano, PhD, Physiotherapy
- Telefonnummer: +34 689105357
- E-Mail: yeray.gonzalez@urjc.es
Studienorte
-
-
Madrid
-
Alcorcón, Madrid, Spanien, 28922
- Rekrutierung
- Universidad Rey Juan Carlos
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Eligibility Criteria The eligibility criteria will be identical for both the experimental and control groups. However, this study will employ a sequential recruitment design. Participants for the control group will be recruited following the experimental group and will be matched (1:1 ratio) based on sex, age (± 5 years), and disease severity according to the Hoehn & Yahr (H&Y) scale.
Inclusion Criteria:
- Subjects diagnosed with Idiopathic Parkinson's Disease according to the UK Parkinson's Disease Society Brain Bank Diagnostic Criteria.
- Subjects staged between 1 and 3 on the Hoehn & Yahr Scale. For matching purposes, stage 1 includes stage 1.5, and stage 2 includes stage 2.5.
Exclusion Criteria:
- Subjects diagnosed with a neurological disease other than PD.
- Those diagnosed with a cardiovascular, respiratory, or metabolic disease or other conditions that represent a contraindication to physical exercise.
- Those who have suffered an exacerbation or hospitalization in the last three months prior to starting the assessment protocol or during the therapeutic intervention process.
- Those who have received a course of steroids, intravenously or orally, six months prior to the start of the study or during the therapeutic intervention process.
- Those with cognitive impairment (defined as a score < 21 on the Montreal Cognitive Assessment, MoCA) or language impairments that prevent adequate communication, comprehension, or following of exercise instructions.
- Participation in a structured, individualized strength and/or aerobic exercise program within the three months prior to enrollment.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Kein Eingriff: Control Group
Participants from the control group will be asked to keep their usual treatment for the duration of the study.
|
|
|
Experimental: Exercise group
Two weekly in-person sessions of multimodal exercise that involve strength training, aerobic interval training / balance and coordination training and a cognitive-motor exercise, each session lasting 55-60 minutes.
Additionally, one weekly home session lasting 25-30 minutes that include strength and aerobic training.
|
In-person session structure: 1) Warm-up for 4 minutes; 2) 4 strength exercises for upper limps, trunk and lower limbs with free weights and elastic bands (3 sets per exercise); 3) Moderate to vigorous aerobic interval training / balance and coordination training (4 stations for 40 seconds, 2 sets); 4) Cognitive-motor exercise for 10 minutes; 5) Stretching and cool-down for 3 minutes. Home session structure: 1) Warm-up for 4 minutes; 2) 3 strength exercises for upper limbs, trunk and lower limbs (3 sets per exercise); 3) Moderate to vigorous aerobic interval training (4 stations for 40 seconds, 2 sets); 4) Stretching and cool-down for 3 minutes |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Consent rate
Zeitfenster: Baseline
|
It will be asessed as the proportion of individuals who provided informed consent relative to the number of individuals invited to participate
|
Baseline
|
|
Recruitment rate
Zeitfenster: Baseline
|
It will be evaluated as the proportion of enrolled participants relative to the number of eligible participants screened
|
Baseline
|
|
Adherence rate
Zeitfenster: Post-intervention (At 12 weeks from the start of the programme)
|
Adherence rate will be assessed as the proportion of completed sessions relative to the scheduled sessions
|
Post-intervention (At 12 weeks from the start of the programme)
|
|
Intervention completion rate
Zeitfenster: Post-intervention (At 12 weeks from the start of the programme)
|
It will be evaluated as the proportion of participants who completed at least 80% of sessions.
|
Post-intervention (At 12 weeks from the start of the programme)
|
|
Trial completion rate
Zeitfenster: At 39 weeks from the start of the programme
|
It will be assessed as the proportion of participants who completed all assessments
|
At 39 weeks from the start of the programme
|
|
Proportion of adverse events
Zeitfenster: Post-intervention (At 12 weeks from the start of the programme)
|
Safety will be reported as the proportion of adverse events, defined as the proportion of participants who experienced adverse events (e.g., falls, pain, fatigue)
|
Post-intervention (At 12 weeks from the start of the programme)
|
|
Treatment-decision rate
Zeitfenster: Post-intervention (At 12 weeks from the start of the programme)
|
Defined as the proportion of exercises that required modification due to fall-risk considerations
|
Post-intervention (At 12 weeks from the start of the programme)
|
|
Change in Theoretical Framework Acceptability Questionnaire
Zeitfenster: At 12 weeks from Baseline
|
It is a questionnaire specifically desgined to assess acceptability of healthcare interventions.
It consists of 7 domains: 1) Affective attitude, 2) Burden, 3) Ethicality, 4)Perceived efectiveness, 5) Intervention coherence, 6) Self efficacy, 7) Opportinity costs 8) General acceptability.
|
At 12 weeks from Baseline
|
|
Client Satisfaction Questionnaire (CSQ-8)
Zeitfenster: Post-intervention (12 weeks from baseline)
|
It contains 8 dimensions measuring satisfaction with the care and treatment received.
The total score is 32 points, with higher scores indicating greater satisfaction.
Dimensions related to satisfaction with the training modality and tool used (entertainment, ease of use, accessibility, among others), the professional who applies it (clear explanation, availability, ability to adapt, among others) or recommendation to other patients will be evaluated.
|
Post-intervention (12 weeks from baseline)
|
|
Average Rating of Perceived Exertion (RPE) during Resistance Training
Zeitfenster: Through study completion (average across 12 weeks)
|
The average perceived effort reported by the participants across all strength training sessions over the 12-week intervention.
This will be assessed using the OMNI-Resistance Exercise Scale (OMNI-RES), which ranges from 0 ("extremely easy") to 10 ("extremely hard").
Higher scores indicate a greater perception of effort during the execution of strength exercises
|
Through study completion (average across 12 weeks)
|
|
Average Rating of Perceived Exertion (RPE) during Cardiorespiratory Exercise
Zeitfenster: Through study completion (average across 12 weeks)
|
The average intensity of effort perceived by the participants during all cardiorespiratory training sessions.
This will be measured using the Borg Rating of Perceived Exertion (RPE) 6-20 Scale.
The scale ranges from 6 (no exertion at all) to 20 (maximal exertion).
This metric reflects the global subjective strain experienced during aerobic activities throughout the 12-week program.
|
Through study completion (average across 12 weeks)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Unified Parkinson Disease Rating Scale Part 3 (UPDRS-3)
Zeitfenster: At 12 weeks from Baseline
|
This scale evaluates the severity of those motor symptoms linked to the disease such as tremor, rigidity, bradikinesia, postural instability and gait distubances.
It consists of 18 items that are scored from 0 (no disturbance) to 4 (maximum disturbance)
|
At 12 weeks from Baseline
|
|
Change in Unified Parkinson Disease Rating Scale Part 3 (UPDRS-3)
Zeitfenster: At 39 weeks from Baseline
|
This scale evaluates the severity of those motor symptoms linked to the disease such as tremor, rigidity, bradikinesia, postural instability and gait distubances.
It consists of 18 items that are scored from 0 (no disturbance) to 4 (maximum disturbance)
|
At 39 weeks from Baseline
|
|
Change in Balance Berg Scale
Zeitfenster: At 12 weeks from Baseline
|
This scale measures static and dynamic balance through 14 tasks.
Each task is scored from 0 (worst score) to 4 (best score)
|
At 12 weeks from Baseline
|
|
Change in Balance Berg Scale
Zeitfenster: At 39 weeks from Baseline
|
This scale measures static and dynamic balance through 14 tasks.
Each task is scored from 0 (worst score) to 4 (best score)
|
At 39 weeks from Baseline
|
|
Change in Non-Motor Symptoms Scale (NMSS)
Zeitfenster: At a 12 weeks from Baseline
|
It is a 30-item rater-based scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease (PD).
The NMSS measures the severity and frequency of non-motor symptoms across nine dimensions: 1) Cardiovascular, 2) Sleep/fatigue, 3) Mood/apathy, 4) Perceptual problems/hallucinations, 5) Attention/memory, 6) Gastrointestinal tract, 7) Urinary, 8) Sexual function and 9) Miscellaneous.
|
At a 12 weeks from Baseline
|
|
Change in Non-Motor Symptoms Scale (NMSS)
Zeitfenster: At a 39 weeks from Baseline
|
It is a 30-item rater-based scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease (PD).
The NMSS measures the severity and frequency of non-motor symptoms across nine dimensions: 1) Cardiovascular, 2) Sleep/fatigue, 3) Mood/apathy, 4) Perceptual problems/hallucinations, 5) Attention/memory, 6) Gastrointestinal tract, 7) Urinary, 8) Sexual function and 9) Miscellaneous.
|
At a 39 weeks from Baseline
|
|
Change in 10 Repetition Maximum (10-RM)
Zeitfenster: At 12 weeks from Baseline
|
The 10-RM is the maximum amount of weight a person can lift exactly 10 times with correct technique, without being able to perform an eleventh repetition.
10-RM for military press with dumbbells, lunges with dumbbells, deadlift with barbell and row with barbell will be assessed.
|
At 12 weeks from Baseline
|
|
Change in Isometric Handgrip Strength
Zeitfenster: At 12 weeks from Baseline
|
A dynamometer is used to measure the maximum handgrip strength with both hands for three times.
The mean is obtained after the three attempts.
|
At 12 weeks from Baseline
|
|
Change in Isometric Handgrip Strength
Zeitfenster: At 39 weeks from Baseline
|
A dynamometer is used to measure the maximum handgrip strength with both hands for three times.
The mean is obtained after the three attempts.
|
At 39 weeks from Baseline
|
|
Change in Dynamic Fatigability
Zeitfenster: At 12 weeks from Baseline
|
A dynamometer is employed and the subject is asked to perform 15 consecutive maximum handgrip contractions.
|
At 12 weeks from Baseline
|
|
Change in Dynamic Fatigability
Zeitfenster: At 39 weeks from Baseline
|
A dynamometer is employed and the subject is asked to perform 15 consecutive maximum handgrip contractions.
|
At 39 weeks from Baseline
|
|
Change in Five Times Sit to Stand Test
Zeitfenster: At 12 weeks from Baseline
|
This test measures lower limbs power.
The subject is asked to stand up and sit down on a chair as quicky as possible for five times while the therapist measures the time.
Two attempts are performed to calculate the mean.
|
At 12 weeks from Baseline
|
|
Change in Five Times Sit to Stand Test
Zeitfenster: At 39 weeks from Baseline
|
This test measures lower limbs power.
The subject is asked to stand up and sit down on a chair as quicky as possible for five times while the therapist measures the time.
Two attempts are performed to calculate the mean.
|
At 39 weeks from Baseline
|
|
Change in 6 Minute Walk Test
Zeitfenster: At 12 weeks from Baseline
|
This test assesses the distance a person is capable to walk as fast as possible for 6 minutes.
|
At 12 weeks from Baseline
|
|
Change in 6 Minute Walk Test
Zeitfenster: At 39 weeks from Baseline
|
This test assesses the distance a person is capable to walk as fast as possible for 6 minutes on a 15 metres long corridor.
|
At 39 weeks from Baseline
|
|
Change in Functional Movement Screen
Zeitfenster: At 12 weeks from Baseline
|
This scale consists of seven motor tasks that measure the quality of movement in different body segments.
Each task is scored from (worst score) 0 to 3 (best score).
|
At 12 weeks from Baseline
|
|
Change in King´s Parkinson´s Disease Pain Scale score
Zeitfenster: At 12 weeks from Baseline
|
Parkinson´s Disease specific scale that evaluates the localization, frequency, and intensity of pain. It has 14 items distributed in 7 domains: 1. Musculoskeletal Pain; 2. Chronic Pain; 3. Fluctuation-related Pain; 4. Nocturnal Pain; 5. Oro-facial Pain; 6. Discoloration, Oedema/Swelling Pain; 7. Radicular Pain. Each item is scored by severity (0, none to 3, very severe) multiplied by frequency (0, never to 4, all the time) resulting in a subscore of 0 to 12, the sum of which gives the total score with a theoretical range from 0 to 168, with higher scores indicating more severity and frequency of pain. |
At 12 weeks from Baseline
|
|
Change in King´s Parkinson´s Disease Pain Scale score
Zeitfenster: At 39 weeks from Baseline
|
Parkinson´s Disease specific scale that evaluates the localization, frequency, and intensity of pain. It has 14 items distributed in 7 domains: 1. Musculoskeletal Pain; 2. Chronic Pain; 3. Fluctuation-related Pain; 4. Nocturnal Pain; 5. Oro-facial Pain; 6. Discoloration, Oedema/Swelling Pain; 7. Radicular Pain. Each item is scored by severity (0, none to 3, very severe) multiplied by frequency (0, never to 4, all the time) resulting in a subscore of 0 to 12, the sum of which gives the total score with a theoretical range from 0 to 168, with higher scores indicating more severity and frequency of pain. |
At 39 weeks from Baseline
|
|
Change in Brief Pain Inventory
Zeitfenster: At 12 weeks from Baseline
|
It assess the severity of pain, impact of pain on daily function, location of pain, pain medications and amount of pain relief in the past 24 hours.
|
At 12 weeks from Baseline
|
|
Change in Brief Pain Inventory
Zeitfenster: At 39 weeks from Baseline
|
It assess the severity of pain, impact of pain on daily function, location of pain, pain medications and amount of pain relief in the past 24 hours.
|
At 39 weeks from Baseline
|
|
Change in Pressure Pain Threshold
Zeitfenster: At 12 weeks from Baseline
|
Two Pain Pressure Thresholds will be measured by a handheld algometer, one over the most painful area (peripheric hyperalgesia) and the other one over the middle of the distal phalanx of the thumb (central hyperalgesia).
The Pain Pressure Threshold will be applied with the algometer perpendicular to the skin increasing at a rate of 1 kg/s until the first sensation of pain. 3 measures with 30-seconds rest between them will be performed, taking the average as Pain Pressure Threshold.
|
At 12 weeks from Baseline
|
|
Change in Pressure Pain Threshold
Zeitfenster: At 39 weeks from Baseline
|
Two Pain Pressure Thresholds will be measured by a handheld algometer, one over the most painful area (peripheric hyperalgesia) and the other one over the middle of the distal phalanx of the thumb (central hyperalgesia).
The Pain Pressure Threshold will be applied with the algometer perpendicular to the skin increasing at a rate of 1 kg/s until the first sensation of pain. 3 measures with 30-seconds rest between them will be performed, taking the average as Pain Pressure Threshold.
|
At 39 weeks from Baseline
|
|
Change in Conditioned Pain Modulation
Zeitfenster: At 12 weeks from Baseline
|
Assesses the descending pain modulatory system.
The Pain Pressure Threshold will be assessed in the middle of the distal phalanx of the thumb with a handheld algometer, corresponding to the first test stimulus.
Afterward, the patient will immerse the contrary hand up to the wrist into stirred ice-cold water (0-4º) maintaining it for 3 minutes corresponding to the conditioning stimulus.
If the pain is unbearable before the 3 minutes, the patient will be able to remove his/her hand.
Immediately after removing the hand, a second Pain Pressure Threshold measure will be performed in the same place as the first one, corresponding to the second test stimulus.
|
At 12 weeks from Baseline
|
|
Change in Conditioned Pain Modulation
Zeitfenster: At 39 weeks from Baseline
|
Assesses the descending pain modulatory system.
The Pain Pressure Threshold will be assessed in the middle of the distal phalanx of the thumb with a handheld algometer, corresponding to the first test stimulus.
Afterward, the patient will immerse the contrary hand up to the wrist into stirred ice-cold water (0-4º) maintaining it for 3 minutes corresponding to the conditioning stimulus.
If the pain is unbearable before the 3 minutes, the patient will be able to remove his/her hand.
Immediately after removing the hand, a second Pain Pressure Threshold measure will be performed in the same place as the first one, corresponding to the second test stimulus.
|
At 39 weeks from Baseline
|
|
Change in Exercise-Induced Hypoalgesia
Zeitfenster: At 12 weeks from Baseline
|
Exercise-Induced Hypoalgesia is a phenomenom in which pain sensitivity is reduced after a single bout of exercise.
Pain sensitivity will be assessed before and immediately after the 6 minute walk test.
Pain sensitivity will be measured with a handheld algometer on the dominant quadriceps and on the non-dominant trapezius for two times.
The algometer will be placed perpendicular to the skin increasing at a rate of 1 kg/s until the first sensation of pain.
|
At 12 weeks from Baseline
|
|
Change in Exercise-Induced Hypoalgesia
Zeitfenster: At 39 weeks from Baseline
|
Exercise-Induced Hypoalgesia is a phenomenom in which pain sensitivity is reduced after a single bout of exercise.
Pain sensitivity will be assessed before and immediately after the 6 minute walk test.
Pain sensitivity will be measured with a handheld algometer on the dominant quadriceps and on the non-dominant trapezius for two times.
The algometer will be placed perpendicular to the skin increasing at a rate of 1 kg/s until the first sensation of pain.
|
At 39 weeks from Baseline
|
|
Change in Tampa Scale of Kinesiophobia
Zeitfenster: At 12 weeks from Baseline
|
Measures fear of movement-related pain.
Its scores range from 11-44 points with higher scores indicating greater fear of pain, movement, and injury
|
At 12 weeks from Baseline
|
|
Change in Tampa Scale of Kinesiophobia
Zeitfenster: At 39 weeks from Baseline
|
Measures fear of movement-related pain.
Its scores range from 11-44 points with higher scores indicating greater fear of pain, movement, and injury
|
At 39 weeks from Baseline
|
|
Pain Catastrophizing Scale
Zeitfenster: At 12 weeks from Baseline
|
Measures catastrophizing thinking.
Its total score range from 0-52, along with three subscale scores assessing rumination, magnification and helplessness, with higher scores indicating higher level of catastrophizing.
|
At 12 weeks from Baseline
|
|
Pain Catastrophizing Scale
Zeitfenster: At 39 weeks from Baseline
|
Measures catastrophizing thinking.
Its total score range from 0-52, along with three subscale scores assessing rumination, magnification and helplessness, with higher scores indicating higher level of catastrophizing.
|
At 39 weeks from Baseline
|
|
Change In Fatigue Severity Scale
Zeitfenster: At 12 weeks from Baseline
|
It is a validated 9-item scale for PD that measures the long-term functional impact of fatigue.
Each item is scored from 1 (Disagree) to 7 (Agree).
|
At 12 weeks from Baseline
|
|
Change In Fatigue Severity Scale
Zeitfenster: At 39 weeks from Baseline
|
It is a validated 9-item scale for PD that measures the long-term functional impact of fatigue.
Each item is scored from 1 (Disagree) to 7 (Agree).
|
At 39 weeks from Baseline
|
|
Change in Parkinson's Disease Sleep Scale 2 (PDSS-2)
Zeitfenster: At 12 weeks from Baseline
|
This scale contains 15 items that measures the level of sleep disruption.
The questionnaire asks about the frequency of the sleep disturbances from "never" to "very often".
|
At 12 weeks from Baseline
|
|
Change in Parkinson's Disease Sleep Scale 2 (PDSS-2)
Zeitfenster: At 39 weeks from Baseline
|
This scale contains 15 items that measures the level of sleep disruption.
The questionnaire asks about the frequency of the sleep disturbances from "never" to "very often".
|
At 39 weeks from Baseline
|
|
Change in State-Trait Anxiety Inventory
Zeitfenster: At 12 weeks from Baseline
|
Measures anxious states and anxious traits.
It has 20 items for assessing trait anxiety and 20 for state anxiety.
All items are rated on a 4-point scale (e.g., from "Almost Never" to "Almost Always").
Higher scores indicate greater anxiety.
|
At 12 weeks from Baseline
|
|
Change in State-Trait Anxiety Inventory
Zeitfenster: At 39 weeks from Baseline
|
Measures anxious states and anxious traits.
It has 20 items for assessing trait anxiety and 20 for state anxiety.
All items are rated on a 4-point scale (e.g., from "Almost Never" to "Almost Always").
Higher scores indicate greater anxiety.
|
At 39 weeks from Baseline
|
|
Change in Beck Depression Inventory
Zeitfenster: At 12 weeks from Baseline
|
Measures depressive symptoms.
Scores range from 0 to 63 leading to 6 groups: 0-10, normal; 11-16, mild mood disturbance; 17-20, borderline clinical depression; 21-30, moderate depression; 31-40, severe depression; and over 40, extreme depression.
|
At 12 weeks from Baseline
|
|
Change in Beck Depression Inventory
Zeitfenster: At 39 weeks from Baseline
|
Measures depressive symptoms.
Scores range from 0 to 63 leading to 6 groups: 0-10, normal; 11-16, mild mood disturbance; 17-20, borderline clinical depression; 21-30, moderate depression; 31-40, severe depression; and over 40, extreme depression.
|
At 39 weeks from Baseline
|
|
Change in Global Physical Activity Questionnaire (GPAQ)
Zeitfenster: At 12 weeks from Baseline
|
It is a questionnaire that consists of 15 questions about physical activity at work, during commutes and in leisure time, and an additional question about sedentary behaviour during a typical week.
This questionnaire provides a numerical result in METs, such that the more active the person is, the more METs the instrument reflects.
|
At 12 weeks from Baseline
|
|
Change in Global Physical Activity Questionnaire (GPAQ)
Zeitfenster: At 39 weeks from Baseline
|
It is a questionnaire that consists of 15 questions about physical activity at work, during commutes and in leisure time, and an additional question about sedentary behaviour during a typical week.
This questionnaire provides a numerical result in METs, such that the more active the person is, the more METs the instrument reflects.
|
At 39 weeks from Baseline
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Mario González Iglesias, Physiotherapy, Universidad Rey Juan Carlos
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 May;18(5):459-480. doi: 10.1016/S1474-4422(18)30499-X. Epub 2019 Mar 14.
- Silverdale MA, Kobylecki C, Kass-Iliyya L, Martinez-Martin P, Lawton M, Cotterill S, Chaudhuri KR, Morris H, Baig F, Williams N, Hubbard L, Hu MT, Grosset DG; UK Parkinson's Pain Study Collaboration. A detailed clinical study of pain in 1957 participants with early/moderate Parkinson's disease. Parkinsonism Relat Disord. 2018 Nov;56:27-32. doi: 10.1016/j.parkreldis.2018.06.001. Epub 2018 Jun 6.
- Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015 Oct;30(12):1591-601. doi: 10.1002/mds.26424.
- Carvalho A, Barbirato D, Araujo N, Martins JV, Cavalcanti JL, Santos TM, Coutinho ES, Laks J, Deslandes AC. Comparison of strength training, aerobic training, and additional physical therapy as supplementary treatments for Parkinson's disease: pilot study. Clin Interv Aging. 2015 Jan 7;10:183-91. doi: 10.2147/CIA.S68779. eCollection 2015.
- Reuter I, Mehnert S, Leone P, Kaps M, Oechsner M, Engelhardt M. Effects of a flexibility and relaxation programme, walking, and nordic walking on Parkinson's disease. J Aging Res. 2011;2011:232473. doi: 10.4061/2011/232473. Epub 2011 Mar 30.
- Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, Bottacchi E, Cannas A, Ceravolo G, Ceravolo R, Cicarelli G, Gaglio RM, Giglia RM, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatrale R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, Dotto PD; PRIAMO study group. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord. 2009 Aug 15;24(11):1641-9. doi: 10.1002/mds.22643.
- Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR; NMSS Validation Group. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord. 2011 Feb 15;26(3):399-406. doi: 10.1002/mds.23462. Epub 2011 Jan 24.
- Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2014 Nov;29(13):1583-90. doi: 10.1002/mds.25945. Epub 2014 Jun 28.
- King LA, Salarian A, Mancini M, Priest KC, Nutt J, Serdar A, Wilhelm J, Schlimgen J, Smith M, Horak FB. Exploring outcome measures for exercise intervention in people with Parkinson's disease. Parkinsons Dis. 2013;2013:572134. doi: 10.1155/2013/572134. Epub 2013 Apr 30.
- Feng H, Li C, Liu J, Wang L, Ma J, Li G, Gan L, Shang X, Wu Z. Virtual Reality Rehabilitation Versus Conventional Physical Therapy for Improving Balance and Gait in Parkinson's Disease Patients: A Randomized Controlled Trial. Med Sci Monit. 2019 Jun 5;25:4186-4192. doi: 10.12659/MSM.916455.
- Ashburn A, Fazakarley L, Ballinger C, Pickering R, McLellan LD, Fitton C. A randomised controlled trial of a home based exercise programme to reduce the risk of falling among people with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2007 Jul;78(7):678-84. doi: 10.1136/jnnp.2006.099333. Epub 2006 Nov 21.
- Kouli A, Torsney KM, Kuan WL. Parkinson's Disease: Etiology, Neuropathology, and Pathogenesis. In: Stoker TB, Greenland JC, editors. Parkinson's Disease: Pathogenesis and Clinical Aspects [Internet]. Brisbane (AU): Codon Publications; 2018 Dec 21. Chapter 1. Available from http://www.ncbi.nlm.nih.gov/books/NBK536722/
- Aschbrenner KA, Kruse G, Gallo JJ, Plano Clark VL. Applying mixed methods to pilot feasibility studies to inform intervention trials. Pilot Feasibility Stud. 2022 Sep 26;8(1):217. doi: 10.1186/s40814-022-01178-x.
- Ernst M, Folkerts AK, Gollan R, Lieker E, Caro-Valenzuela J, Adams A, Cryns N, Monsef I, Dresen A, Roheger M, Eggers C, Skoetz N, Kalbe E. Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2024 Apr 8;4(4):CD013856. doi: 10.1002/14651858.CD013856.pub3.
- Danoudis M, Iansek R. A long-term community gym program for people with Parkinson's disease: a feasibility study of the Monash Health "Health and Fitness" model. Disabil Rehabil. 2022 Nov;44(23):7330-7338. doi: 10.1080/09638288.2021.1977396. Epub 2021 Sep 21.
- Morris ME, Taylor NF, Watts JJ, Evans A, Horne M, Kempster P, Danoudis M, McGinley J, Martin C, Menz HB. A home program of strength training, movement strategy training and education did not prevent falls in people with Parkinson's disease: a randomised trial. J Physiother. 2017 Apr;63(2):94-100. doi: 10.1016/j.jphys.2017.02.015. Epub 2017 Mar 14.
- Avenali M, Picascia M, Tassorelli C, Sinforiani E, Bernini S. Evaluation of the efficacy of physical therapy on cognitive decline at 6-month follow-up in Parkinson disease patients with mild cognitive impairment: a randomized controlled trial. Aging Clin Exp Res. 2021 Dec;33(12):3275-3284. doi: 10.1007/s40520-021-01865-4. Epub 2021 May 12.
- Gobbi LTB, Pelicioni PHS, Lahr J, Lirani-Silva E, Teixeira-Arroyo C, Santos PCRD. Effect of different types of exercises on psychological and cognitive features in people with Parkinson's disease: A randomized controlled trial. Ann Phys Rehabil Med. 2021 Jan;64(1):101407. doi: 10.1016/j.rehab.2020.05.011. Epub 2020 Oct 6.
- Mylius V, Perez Lloret S, Cury RG, Teixeira MJ, Barbosa VR, Barbosa ER, Moreira LI, Listik C, Fernandes AM, de Lacerda Veiga D, Barbour J, Hollenstein N, Oechsner M, Walch J, Brugger F, Hagele-Link S, Beer S, Rizos A, Chaudhuri KR, Bouhassira D, Lefaucheur JP, Timmermann L, Gonzenbach R, Kagi G, Moller JC, Ciampi de Andrade D. The Parkinson disease pain classification system: results from an international mechanism-based classification approach. Pain. 2021 Apr 1;162(4):1201-1210. doi: 10.1097/j.pain.0000000000002107.
- Broen MP, Braaksma MM, Patijn J, Weber WE. Prevalence of pain in Parkinson's disease: a systematic review using the modified QUADAS tool. Mov Disord. 2012 Apr;27(4):480-4. doi: 10.1002/mds.24054. Epub 2012 Jan 9.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 090420253882025
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
IPD-Sharing-Zeitrahmen
IPD-Sharing-Zugriffskriterien
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- ICF
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .